Find policies, billing codes, payers, states, and providers
HCPCS J9010: Injection, Alemtuzumab 10 mg
HCPCS Level II code J9010 denotes the injectable monoclonal antibody alemtuzumab, billed per 10 mg unit. As an infused biologic used in oncology and hematology practices, this code is central to billing for specialty drug administration in infusion centers and hospital outpatient settings. Nationally, accurate reporting of J9010 affects reimbursement, utilization tracking, and cost analyses for high-cost oncology therapeutics.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for alemtuzumab use, common ICD-10 diagnoses associated with its administration, payer coverage patterns, and comparisons to related biologic codes. The publication outlines typical sites of service, coding relationships, and benchmarking considerations relevant to revenue cycle and clinical operations teams.
This summary provides practical reference material for billing staff, practice managers, and policy analysts seeking clarity on code purpose, payer scope, and what to expect when J9010 appears on service lines. Data not available in the input is noted where applicable.
Customize your policy alerts
Sign up for hcpcs J9010 policy alerts
Get alerted when payer policies referencing J9010 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J9010 represents the injection formulation of alemtuzumab, measured per 10 mg. This code is used to bill for administration of alemtuzumab, a monoclonal antibody therapy indicated for certain hematologic and oncologic conditions.
-
Service type: Injectable biologic therapeutic agent
-
Typical site of service: Infusion center or hospital outpatient infusion setting
National Reimbursement Benchmarks
Commercial national benchmarks for J9010 center on a BUCA average commercial rate of $701.5, positioning it between Blue Cross Blue Shield and Cigna. Blue Cross Blue Shield’s distribution is very tight with a P75–P25 range of $28.0 (P75 $663.4 minus P25 $663.4 yields $0.0 actual spread if using given identical percentiles, but using provided values the computed interquartile difference is $0.0), while Cigna shows a markedly wider interquartile spread of $179.0 ($873.0 minus $694.3). Blue Cross Blue Shield’s mean and median cluster near the top of its narrow band around $659–$663, whereas Cigna’s higher mean and max elevate its central tendency despite greater dispersion.
Variation implies differing contract dynamics: Blue Cross Blue Shield exhibits the tightest rate clustering, BUCA sits at a higher average without min/max reporting, and Cigna displays the widest IQR-driven dispersion reflecting broader pricing outcomes. These comparisons highlight where commercial rate concentration is strongest and where price variability is most pronounced.